Multi‐marker algorithms based on CXCL13, IL‐10, sIL‐2 receptor, and β2‐microglobulin in cerebrospinal fluid to diagnose CNS lymphoma

Autor: Yuichi Fujita, Masahiro Maeyama, Masamitsu Nishihara, Takanori Hirose, Hirotomo Tanaka, Masaaki Kohta, Kazuhiro Tanaka, Satoshi Nakamizo, Kenji Sekiguchi, Eiji Kohmura, Takashi Sasayama, Katsu Mizukawa, Tomoo Itoh
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Cancer Research
Central nervous system
lcsh:RC254-282
cerebrospinal fluid
IL‐10
Central Nervous System Neoplasms
03 medical and health sciences
0302 clinical medicine
Cerebrospinal fluid
Biopsy
medicine
Biomarkers
Tumor
Humans
Radiology
Nuclear Medicine and imaging
central nervous system lymphoma
Prospective Studies
CXCL13
Prospective cohort study
Original Research
Retrospective Studies
medicine.diagnostic_test
Beta-2 microglobulin
business.industry
Lymphoma
Non-Hodgkin
Clinical Cancer Research
Receptors
Interleukin-2
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Chemokine CXCL13
Lymphoma
Interleukin-10
Interleukin 10
030104 developmental biology
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Case-Control Studies
IL-10
biomarker
business
beta 2-Microglobulin
Algorithm
Algorithms
Follow-Up Studies
Zdroj: Cancer Medicine
Cancer Medicine, Vol 9, Iss 12, Pp 4114-4125 (2020)
ISSN: 2045-7634
Popis: Tumor biopsy is essential for the definitive diagnosis of central nervous system (CNS) lymphoma. However, the biopsy procedure carries the risk of complications such as bleeding, convulsions, and infection. Cerebrospinal fluid (CSF) β2‐microglobulin (β2‐MG), soluble IL‐2 receptor (sIL‐2R), and interleukin‐10 (IL‐10) are known to be useful diagnostic biomarkers for CNS lymphoma. The C‐X‐C motif chemokine ligand 13 (CXCL13) was recently reported to be another useful biomarker for CNS lymphoma. The purpose of this study is to establish a diagnostic algorithm that can avoid biopsy by combining these diagnostic biomarkers. In the first, we conducted a case‐control study (n = 248) demonstrating that the CSF CXCL13 concentration was significantly increased in CNS lymphoma patients compared with various other brain diseases (AUC = 0.981). We established a multi‐marker diagnostic model using CSF CXCL13, IL‐10, β2‐MG, and sIL‐2R from the results of the case‐control study and then applied the model to a prospective study (n = 104) to evaluate its utility. The multi‐marker diagnostic algorithms had excellent diagnostic performance: the sensitivity, specificity, positive predictive value, and negative predictive value were 97%, 97%, 94%, and 99%, respectively. In addition, CSF CXCL13 was a prognostic biomarker for CNS lymphoma patients. Our study suggests that multi‐marker algorithms are important diagnostic tools for patients with CNS lymphoma.
A comparison of the cerebrospinal fluid (CSF) concentrations of CXCL13 between CNS lymphomas and other CNS diseases. The CSF CXCL13 levels of CNS lymphoma were significantly higher than those of the other diseases. The CXCL13 expression levels increased in the CNS lymphoma specimens compared with the other tumor specimens. The multi‐marker prediction algorithms based on CSF CXCL13, IL‐10, sIL‐2R, and β2‐MG had excellent diagnostic performance.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje